Brensocatib (Brinsupri) for Non-Cystic Fibrosis Bronchiectasis
For patients aged 12 years or older with non-cystic fibrosis bronchiectasis, start brensocatib at either 10 mg or 25 mg orally once daily with or without food. 1
Starting Dose
The FDA-approved dosing options are:
- 10 mg once daily, OR
- 25 mg once daily
Both doses are taken orally with or without food 1. The 25 mg dose demonstrated superior disease-modifying effects in the ASPEN trial, specifically reducing lung function decline (FEV1 decline of 24 ml vs 62 ml with placebo, p=0.04) and nominally improving patient-reported symptoms 2. Both doses significantly reduced annualized exacerbation rates by approximately 19-21% compared to placebo 2.
Practical consideration: If a dose is missed, take the next dose at the regular time the following day—do not double the dose 1.
Contraindications
There are no contraindications to brensocatib 1. This is notable and simplifies prescribing decisions.
Monitoring Schedule
Dermatologic Monitoring
Monitor patients for development of new rashes or skin conditions throughout treatment 1. The mechanism of DPP-1 inhibition can cause:
- Rash
- Dry skin
- Hyperkeratosis (incidence 1-4%, predominantly mild-to-moderate) 3
Action required: Refer patients to dermatology for evaluation of any new dermatologic findings 1.
Dental/Periodontal Monitoring
Brensocatib increases risk of gingival and periodontal adverse reactions 1. This relates to the drug's mechanism mimicking aspects of Papillon-Lefèvre syndrome phenotype 3.
Action required:
- Refer patients to dental care services for regular dental checkups while on treatment 1
- Advise patients to perform routine dental hygiene 1
General Monitoring
While the FDA label doesn't specify exact monitoring intervals, the ASPEN trial evaluated patients over 52 weeks 2. Based on standard bronchiectasis care principles from ERS guidelines, patients should be assessed at minimum annually, with more frequent monitoring in severe disease 4.
Pregnancy Precautions
The FDA label does not provide specific pregnancy category information or contraindications for pregnancy 1. This represents a gap in the prescribing information that requires clinical judgment and shared decision-making with patients of childbearing potential.
Live Attenuated Vaccines
Avoid live attenuated vaccines during brensocatib treatment 1. The concomitant use has not been evaluated, and it is unknown whether administration will affect vaccine safety or effectiveness 1.
Clinical Context for Use
Brensocatib works by inhibiting dipeptidyl peptidase 1 (DPP-1), thereby preventing activation of neutrophil serine proteases that drive neutrophilic inflammation in bronchiectasis 2, 3. In the pivotal ASPEN trial of 1,721 patients treated for 52 weeks, both doses significantly prolonged time to first exacerbation (hazard ratio 0.81 for 10 mg, 0.83 for 25 mg) and increased the proportion remaining exacerbation-free at week 52 (48.5% vs 40.3% with placebo) 2.
Important caveat: The overall incidence of adverse events was similar across groups, except for higher incidence of hyperkeratosis with brensocatib 2. This favorable safety profile, combined with no contraindications, makes it accessible for most patients with bronchiectasis aged ≥12 years.